Septic shock, caused by exaggerated host responses to various microbial products typified by lipopolysaccharide (LPS), remains the leading cause of death in trauma patients. Gaining insight into the nature of host interactions with LPS will certainly facilitate attempts to develop effective anti-sepsis drugs. Tremendous progress has been made during the past few years in understanding the mechanisms of pathogen-induced host responses. Toll-like receptor (TLR) 4 and 2 have been implicated as major receptors for signaling initiated by LPS and many other microbial products following their binding to CD14. In addition, many signaling intermediates involved in LPSinduced cell activation, particularly activation of the transcription factor NF-κB, have been identified and characterized. Further investigations with these molecules will certainly reward us with more effective therapeutic drugs to treat septic shock as well as many other inflammatory and infectious disorders.
References
1.
Parrillo JEPathogenetic mechanisms of septic shock. N Engl J Med1993; 328: 1471—1477.
2.
Stone R.Search for sepsis drugs goes on despite past failures. Science1994; 264: 365—367.
3.
Warren HSStrategies for the treatment of sepsis. N Engl J Med1997; 336: 952—953.
4.
Ghosh S., May MJ, Kopp EBNF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol1998; 16: 225—260.
5.
May MJ, Ghosh S.Signal transduction through NF-kappa B. Immunol Today1998; 19: 80—88.
6.
Wright SDCD14 and innate recognition of bacteria. J Immunol1995; 155: 6—8.
7.
Ulevitch RJ, Tobias PSReceptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol1995; 13: 437—457.
8.
Ulevitch RJ, Tobias PSRecognition of Gram-negative bacteria and endotoxin by the innate immune system . Curr Opin Immunol1999; 11: 19—22.
9.
O'Neill LA, Greene C.Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants. J Leukoc Biol1998; 63: 650—657.
10.
Kopp EB, Medzhitov R.Toll-receptor family and control of innate immunity. Curr Opin Immunol1999; 11: 13—18.
11.
Anderson KVToll signaling pathways in the innate immune response. Curr Opin Immunol2000; 12: 13—19.
12.
Poltorak A. , He X., Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science1998; 282: 2085—2088.
13.
Qureshi ST, Lariviere L., Leveque G. et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4. J Exp Med1999; 189: 615—625.
14.
Hoshino K., Takeuchi O., Kawai T. et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product . J Immunol1999; 162: 3749—3752.
15.
Arbour NC, Lorenz E., Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet2000; 25: 187—191.
16.
Shimazu R., Akashi S., Ogata H. et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med1999; 189: 1777—1782.
17.
Akashi S., Ogata H., Kirikae F. et al. Regulatory roles for CD14 and phosphatidylinositol in the signaling via Toll-like receptor 4-MD-2. Biochem Biophys Res Commun2000; 268: 172—177.
18.
Thieblemont N., Wright SDTransport of bacterial lipopolysaccharide to the Golgi apparatus. J Exp Med1999; 190: 523—534.
19.
Underhill DM , Ozinsky A., Hajjar AM et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature1999; 401: 811—815.
20.
Belvin MP, Anderson KVA conserved signaling pathway: the Drosophila Toll-dorsal pathway. Annu Rev Cell Dev Biol1996; 12: 393—416.
21.
Janeway Jr CA, Medzhitov R.Lipoproteins take their toll on the host. Curr Biol1999; 9: R879—R882.
22.
Hirschfeld M., Ma Y., Weis JH, Vogel SN, Weis JJCutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol2000; 165: 618—622.
23.
Kang AD, Wong PM, Chen H., Castagna R., Chung SW, Sultzer BMRestoration of lipopolysaccharide-mediated B-cell response after expression of a cDNA encoding a GTP-binding protein. Infect Immun1996; 64: 4612—6417.
24.
Wong PM, Kang A., Chen H. et al. Lps(d)/Ran of endotoxin-resistant C3H/HeJ mice is defective in mediating lipopolysaccharide endotoxin responses. Proc Natl Acad Sci USA1999; 96: 11543—11548.
25.
Kawai T., Adachi O., Ogawa T., Takeda K., Akira S.Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity1999; 11: 115—122.
26.
Swantek JL, Tsen MF, Cobb MH, Thomas JAIL-1 receptor-associated kinase modulates host responsiveness to endotoxin . J Immunol2000; 164: 4301—4306.
27.
Lomaga MA, Yeh WC, Sarosi I. et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev1999; 13: 1015—1024.
28.
Li ZW, Chu W., Hu Y. et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med1999; 189: 1839—1845.
29.
Rudolph D., Yeh WC, Wakeham A. et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev2000 ; 14: 854—862.
30.
Hu Y., Baud V., Delhase M. et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science1999; 284: 316—320.
31.
Wesche H., Gao X., Li X., Kirschning CJ, Stark GR, Cao Z.IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem1999; 274: 19403—19410.
32.
Kopp E., Medzhitov R., Carothers J. et al. ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway. Genes Dev1999 ; 13: 2059—2071.
33.
Takaesu G., Kishida S., Hiyama A. et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPΚ by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell2000; 5: 649—658.
34.
Ling L., Goeddel DVT6BP, a TRAF6-interacting protein involved in IL-1 signaling. Proc Natl Acad Sci USA2000; 97: 9567—9572.
35.
Adachi O., Kawai T., Takeda K. et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity1998 ; 9: 143—150.
